Interview with Kalman Petro, Managing Director, Actavis BV
A very strong phrase that we recently came across describes a “war going on in the generics industry” as a result of the preference policy, which people have claimed has…
Address: Main building, Archimedesweg 4-6, 2333 CN Leiden,Netherlands
Tel: +31(0) 71 519 91 00
Crucell is a global biopharmaceutical company dedicated to bringing meaningful innovation to global health. We do this by discovering, developing, manufacturing and marketing products that combat major threats to the health of people worldwide. Our specialty is fighting infectious diseases—a growing healthcare challenge.
Innovation is the drive force behind our strong research & development (R&D) pipeline, with promising products in pre-clinical and clinical development. Crucell product candidates include flu-mAb, and antibody product effective against a broad range of influenza virus strains, tuberculosis and malaria vaccines, as well as a rabies monoclonal antibody combination-all produced on our unique PER.C6® human-cell technology.
Currently we are combating twelve major infectious diseases with our range of marketed vaccines in the paediatric, travel & endemic and respiratory fields. We are the largest independent vaccine company in the world.
Our vaccine business provides stable and predictable sales and cash flow. In 2009, we sold more than 115 million vaccine doses in over 100 countries throughout the world, which makes us the largest independent vaccine player. Within vaccines we operate in three main markets: paediatric, travel & endemic, and respiratory.
A very strong phrase that we recently came across describes a “war going on in the generics industry” as a result of the preference policy, which people have claimed has…
Bioceros was founded as a service company built on the immunology expertise of its founders. Additional cell line expertise was added when you joined in 2007. What made this combination…
Clearly the end of 2010 was an exciting time for you. As you entered the transition period as the new CEO of OctoPlus, you also participated in the equity raising.…
As the founder of the Institute of Young Entrepreneurs at the Delft University of Technology and an enthusiastic promoter of innovation and new technologies, what do you believe distinguishes a…
We do not often meet companies that have been successful at retaining their manufacturing facilities in the Netherlands. How and why did former Katwijk Farma -and now Apotex- succeed to…
Pfizer is well placed for the next generation of growth. Coming off great M&A’s and now restructuring internally, (from the country structure to the business units). After closing 2010, the…
Certain cities have specific institutions, foundations, or in this case, science parks that serve as a microcosm for that city. How does Utrecht Science Park embody the identity and strengths…
While doing our research we couldn’t help but notice that you are quite passionate about issues related to healthcare and an avid proponent of healthcare reform. In this vein, what…
IMS Health sets itself apart because of its global reach, while mastering local expertise. Clearly, every market is one of a kind. What is so particular about the Dutch market?…
As the chairman of a consortium that has been working towards both medical and technological progress in the region, how have you seen this progress taking place in the Netherlands…
Deloitte is renowned for its strong network of international expertise. Yet every market has its own particularities… Having spent 16 years with the company, in your opinion, what is it…
Your role as Chair of the Executive Board is a mix between CEO and CMO. On a daily basis, which do you see yourself as more – the Chief Executive…
See our Cookie Privacy Policy Here
